Neuroradiologische Klinik, Klinikum Stuttgart, Kriegsbergstraße 60, 70174, Stuttgart, Germany.
Neurochirurgische Klinik, Klinikum Stuttgart, Stuttgart, Germany.
Clin Neuroradiol. 2020 Dec;30(4):835-842. doi: 10.1007/s00062-019-00846-5. Epub 2019 Nov 4.
Reports about the use of flow diverter stents (FDS) in the acute setting of subarachnoid hemorrhage (SAH) are limited. This article presents a single center experiences based on 45 consecutive cases with emphasis on complication rates and clinical and radiologic outcomes.
A prospectively maintained database of all cases treated with FDS as a stand-alone or adjunct device was retrospectively reviewed. All patients treated within 30 days of SAH were included. Records were made of clinical presentation, details of endovascular treatment, procedural complications, clinical outcome, and degree of occlusion on follow-up.
In this study 45 patients (48.9% females; mean age 58.8 ± 12.4 years) were included. Flow diversion was performed after a median of 4 days. The procedural complication rate was 13.3% resulting in 2.2% permanent morbidities and 4.4% mortalities. No major hemorrhagic complications related to antiplatelet therapy were recorded. Immediate complete occlusion was achieved in 13.3%. Among survivors, complete occlusion was achieved in 94.6%. Excellent clinical outcome was recorded in 68.9% and 81.6% of the total population and survivors, respectively. There were no records of rebleeding from the target lesions.
Flow diversion is an attractive alternative strategy for management of acutely ruptured aneurysms with high rates of delayed complete occlusion and acceptable complication rates.
关于血流导向装置(FDS)在蛛网膜下腔出血(SAH)急性期应用的报道有限。本文介绍了单中心的经验,共 45 例连续病例,重点关注并发症发生率和临床及影像学结果。
回顾性分析了所有使用 FDS 作为独立或辅助装置治疗的病例的前瞻性维护数据库。所有在 SAH 后 30 天内接受治疗的患者均被纳入研究。记录了临床症状、血管内治疗细节、手术并发症、临床结局以及随访时的闭塞程度。
本研究共纳入 45 例患者(48.9%为女性;平均年龄 58.8±12.4 岁)。FDS 治疗的中位数时间为 4 天。手术并发症发生率为 13.3%,导致 2.2%的永久性并发症和 4.4%的死亡率。未记录到与抗血小板治疗相关的主要出血性并发症。即刻完全闭塞率为 13.3%。在幸存者中,完全闭塞率为 94.6%。总人群和幸存者的优良临床结局分别为 68.9%和 81.6%。目标病变无再出血记录。
血流导向装置是急性破裂动脉瘤的一种有吸引力的治疗策略,具有较高的迟发性完全闭塞率和可接受的并发症发生率。